tiprankstipranks
Trending News
More News >
Bubs Australia Ltd. (AU:BUB)
:BUB
Australian Market

Bubs Australia Ltd. (BUB) AI Stock Analysis

Compare
41 Followers

Top Page

AU

Bubs Australia Ltd.

(Sydney:BUB)

Rating:48Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
The overall stock score is primarily influenced by weak financial performance due to ongoing losses and cash flow challenges. Technical analysis provides some positive signals with strong upward momentum, but overbought conditions pose a risk. Valuation metrics are unfavorable with a negative P/E ratio and no dividend yield.

Bubs Australia Ltd. (BUB) vs. iShares MSCI Australia ETF (EWA)

Bubs Australia Ltd. Business Overview & Revenue Model

Company DescriptionBubs Australia Ltd. (BUB) is an Australian company primarily engaged in the production and distribution of premium infant nutrition products. The company specializes in goat milk infant formula, organic baby food, and other nutritional products tailored for infants and toddlers. Bubs Australia operates within the consumer goods sector, focusing on offering high-quality, organic, and health-conscious options to meet the dietary needs of young children.
How the Company Makes MoneyBubs Australia Ltd. generates revenue through the sale of its infant nutrition products, with a strong focus on goat milk infant formula and organic baby food. The company's key revenue streams include retail sales through supermarkets, pharmacies, and online platforms both domestically and in international markets, particularly in Asia. Bubs Australia has established significant partnerships and distribution agreements to expand its market presence. The company's earnings are also bolstered by its emphasis on premium, organic products, positioning itself as a trusted brand among health-conscious parents seeking high-quality nutrition for their children.

Bubs Australia Ltd. Financial Statement Overview

Summary
Bubs Australia Ltd. shows some revenue growth but suffers from consistent losses and considerable cash flow challenges. Profitability and cash generation need improvement, despite a low leverage balance sheet.
Income Statement
45
Neutral
Bubs Australia Ltd. shows fluctuating revenue figures with a notable increase in the latest year. However, the company consistently reports negative EBIT and net income, indicating ongoing operational challenges. The gross profit margin has improved significantly, but net profit margins remain negative, reflecting profitability issues.
Balance Sheet
40
Negative
The company's debt-to-equity ratio is relatively low, suggesting limited leverage. However, the return on equity is negative due to persistent losses, and the equity ratio indicates a moderate proportion of equity financing. The balance sheet overall shows a stable asset base but needs improvement in profitability and equity returns.
Cash Flow
38
Negative
Cash flows are negative, with the operating and free cash flow being significantly negative, indicating cash burn. There is a slight improvement in free cash flow growth, but the company faces challenges in generating positive operating cash flow. The cash flow to net income ratios are not favorable, reflecting poor cash conversion from operations.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue88.82M79.70M60.11M89.30M39.31M54.64M
Gross Profit43.91M38.70M-11.68M26.21M-10.68M6.64M
EBITDA-15.07M-19.42M-104.29M-7.82M-73.04M-11.14M
Net Income-9.76M-20.99M-108.35M-11.38M-74.74M-7.77M
Balance Sheet
Total Assets69.59M66.75M65.60M125.94M105.92M161.51M
Cash, Cash Equivalents and Short-Term Investments17.24M17.52M26.05M16.31M27.88M26.03M
Total Debt6.35M7.00M4.41M4.92M4.16M4.59M
Total Liabilities30.90M29.88M23.92M37.73M18.90M29.61M
Stockholders Equity38.69M36.87M41.68M88.21M87.02M131.90M
Cash Flow
Free Cash Flow-14.73M-26.52M-46.74M-9.93M-23.24M-22.14M
Operating Cash Flow-14.58M-26.33M-46.49M-9.37M-22.63M-21.92M
Investing Cash Flow-169.76K-189.82K-4.25M-1.56M-5.60M-8.70M
Financing Cash Flow4.08M17.99M60.48M-643.21K30.09M33.35M

Bubs Australia Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.18
Price Trends
50DMA
0.14
Positive
100DMA
0.13
Positive
200DMA
0.13
Positive
Market Momentum
MACD
0.01
Negative
RSI
67.61
Neutral
STOCH
75.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BUB, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.14, and above the 200-day MA of 0.13, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 67.61 is Neutral, neither overbought nor oversold. The STOCH value of 75.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BUB.

Bubs Australia Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
€15.34B13.05-4.03%3.83%-1.58%-101.37%
AUCLV
60
Neutral
AU$91.85M20.306.80%2.73%15.48%135.65%
AUCLV
60
Neutral
AU$91.85M20.306.80%2.73%15.48%135.65%
AUMBH
49
Neutral
AU$23.38M-33.40%-13.09%-139.06%
AUMBH
49
Neutral
AU$23.38M-33.40%-13.09%-139.06%
AUBUB
48
Neutral
AU$160.76M-21.85%30.54%88.42%
AUNUC
45
Neutral
AU$23.47M-47.74%43.14%51.35%
AUNUC
45
Neutral
AU$23.47M-47.74%43.14%51.35%
AUNOU
43
Neutral
AU$31.87M
4.22%-199.40%
AUNOU
43
Neutral
AU$31.87M
4.22%-199.40%
AUAHF
41
Neutral
AU$31.22M-23.00%-2.14%11.40%
AUAHF
41
Neutral
AU$31.22M-23.00%-2.14%11.40%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BUB
Bubs Australia Ltd.
0.18
0.05
38.46%
AU:AHF
Australian Dairy Nutritionals Group
0.04
0.02
100.00%
AU:AHF
Australian Dairy Nutritionals Group
0.04
0.02
100.00%
AU:NOU
Noumi Limited
0.12
0.00
0.00%
AU:NOU
Noumi Limited
0.12
0.00
0.00%
AU:NUC
Nuchev Pty Ltd
0.16
-0.04
-20.00%
AU:NUC
Nuchev Pty Ltd
0.16
-0.04
-20.00%
AU:CLV
Clover Corporation Limited
0.54
0.06
12.50%
AU:CLV
Clover Corporation Limited
0.54
0.06
12.50%
AU:MBH
Maggie Beer Holdings Ltd.
0.07
0.01
16.67%

Bubs Australia Ltd. Corporate Events

Bubs Australia Ltd. Issues Unquoted Securities for Employee Incentive
Jul 4, 2025

Bubs Australia Ltd. announced the issuance of over 10 million unquoted securities as part of an employee incentive scheme, set to vest in June 2027. This move is likely aimed at aligning employee interests with long-term company performance, potentially impacting the company’s operational strategy and market positioning by fostering a motivated workforce.

The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.

Bubs Australia Advances Towards Permanent US Market Access with FDA Submission
Jun 15, 2025

Bubs Australia Ltd. has submitted its New Infant Formula Submission to the US FDA, marking a crucial step towards securing permanent regulatory approval in the US market. This move is part of Bubs’ strategy to solidify its position in the US, its largest market, and is expected to enhance its growth prospects. The successful completion of a large-scale clinical trial in the US underscores Bubs’ technical and operational capabilities, positioning it as a credible global manufacturer in the dairy industry.

The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.

Bubs Australia Wins $26.5 Million in Legal Dispute
Apr 29, 2025

Bubs Australia Ltd. announced a favorable outcome in a legal dispute involving its subsidiary, The Infant Food Co. Pty Limited, against Alice Trading Limited and Willis Trading Limited, subsidiaries of Alpha Professional Holdings Ltd. The Australian Centre for International Commercial Arbitration awarded Bubs a total of $26.5 million for debt, breach of contract, and damages claims. This outcome strengthens Bubs’ financial position and underscores its ability to successfully navigate complex legal challenges, potentially enhancing its standing in the industry.

Bubs Australia Reports Strong Q3 FY25 Performance with Positive Cash Flow
Apr 28, 2025

Bubs Australia Limited reported a positive operating cash flow for the second consecutive quarter, with a notable improvement in financial performance for Q3 FY25. The company achieved a group net revenue of $23.2 million, a 52.6% increase from the previous corresponding period, and a significant reduction in EBITDA loss. Bubs is making progress in the USA market, with strong sales growth on platforms like Amazon and in physical stores, partly due to competitors’ supply shortages. The company is also advancing its clinical trials in the USA, aiming for FDA approval later in the year, which could further enhance its market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025